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Summary The novel antifolate lometrexol (5,10-dideazatetrahydrofolate) inhibits de novo purine biosynthesis, and co-incubation with
hypoxanthine abolishes its cytotoxicity. The prevention of hypoxanthine rescue from an antipurine antifolate by the nucleoside transport
inhibitor dipyridamole was investigated for the first time in nine human and rodent cell lines from seven different tissues of origin. In A549,
HeLa and CHO cells, dipyridamole prevented hypoxanthine rescue and so growth was inhibited by the combination of lometrexol,
dipyridamole and hypoxanthine, but in HT29, HCT116, KK47, MDA231, CCRF CEM and L1210 cells dipyridamole had no effect and the
combination did not inhibit growth. Dipyridamole inhibited hypoxanthine uptake in A549 but not in CCRF CEM cells. Dipyridamole prevented
the hypoxanthine-induced repletion of dGTP pools, depleted by lometrexol, in A549 but not in CCRF CEM cells. Thus, the selective growth-
inhibitory effect of the combination of lometrexol, dipyridamole and hypoxanthine is apparently due to the dipyridamole sensitivity (ds) or
insensitivity (di) of hypoxanthine transport. Both the human and murine leukaemic cells are of the di phenotype. If this reflects the transport
phenotype of normal bone marrow it would suggest that the combination of lometrexol, dipyridamole and hypoxanthine might be selectively
toxic to certain tumour types and have reduced toxicity to the bone marrow.
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Host toxicity and drug resistance are major obstacles to effective
and safe chemotherapy, and there is a continuing search for
chemotherapeutic combinations that will overcome them. The
antifolate lometrexol (5,10-dideaza-5,6,7,8-tetrahydrofolate:
DDATHF) represents a novel approach to antifolate chemotherapy
as its target for inhibition is glycinamide ribonucleotide trans-
formylase, the first folate-dependent enzyme of de novo purine
biosynthesis (Beardsley et al, 1989). Clinically, lometrexol has
been associated with some myelosuppression and gastrointestinal
toxicity (Nelson et al, 1990; Young et al, 1990; Paganini et al,
1992; Ray et al, 1993) which may be prevented by folic or folinic
acid supplementation before and after dosing with lometrexol.
This has, however, the potential for a parallel reduction in the anti-
tumour activity of lometrexol, although this has not been demon-
strated clinically. A means of either selectively increasing the
anti-tumour activity or reducing the dose-limiting toxicities, or
both, would therefore be desirable.
Resistance to antimetabolite inhibitors of de novo nucleotide
biosynthesis may arise as a result of salvage of extracellular
nucleosides and nucleobases leading to repletion of intracellular
nucleotide pools. Clinically, this may be exacerbated by two
factors. First, malignant cells frequently have higher salvage
activity than normal cells (Fox et al, 1991; Kinsella and Harran,
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1991). Second, release of nucleic acids from dead cells and their
breakdown can result in locally high concentrations ofsalvageable
nucleosides and bases in tumours.
The nucleoside transport inhibitor dipyridamole has been used
successfully in vitro and to a limited extent in animals and in
cancer patients to increase the cytotoxicity of antimetabolites by
blocking the uptake of nucleosides for salvage (reviewed by Goel
and Howell, 1991). Less is known about the modulation of
antimetabolite cytotoxicity via the effect of dipyridamole on
nucleobase transport. However, in a review of published data,
Plagemann et al (1988) observed that dipyridamole could inhibit
hypoxanthine transport in five out of seven rodent cell lines.
Furthermore, Chan and Howell (1990) demonstrated the potentia-
tion of methotrexate cytotoxicity in ovarian cancer cells by dipyri-
damole by inhibition of not only thymidine but also hypoxanthine
uptake. Cells treated with lometrexol have reduced ATP and GTP
pools; co-incubation with hypoxanthine both repletes these pools
(Pizzorno et al, 1991) and abolishes the cytotoxic effect of lome-
trexol (Erba et al, 1994). Thus, dipyridamole should enhance
lometrexol cytotoxicity by the inhibition ofhypoxanthine uptake.
We report here an investigation of the efficacy of dipyridamole
at preventing hypoxanthine-mediated rescue from lometrexol
growth inhibition in a range of human and rodent cell lines
(selected to reflect some of the common human malignancies).
Hypoxanthine was used at 30 gM in these studies as this represents
a physiologically relevant concentration (Tattersall et al, 1983) and
dipyridamole was used at 10 gtM as this concentration has been
shown to inhibit hypoxanthine transport > 90% in other cell lines
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(Plagemann and Wohlhueter, 1984a). We believe that this is the
first study of the potentiation of an antipurine antifolate by the
nucleoside transport inhibitor dipyridamole.
We found that the cells were oftwo types: those in which dipyri-
damole could inhibit hypoxanthine rescue and those in which
dipyridamole could not prevent hypoxanthine rescue. The uptake
ofhypoxanthine in two ofthe cell lines (representing the two types
ofcell) was measured in the presence and absence ofdipyridamole
and nitrobenzylthioinosine (NBTI), another nucleoside transport
inhibitor. We observed that hypoxanthine uptake was not sensitive
to NBTI in either cell line. However, the two cell lines displayed a
differential sensitivity to dipyridamole, corresponding to the
prevention ofhypoxanthine rescue from lometrexol in growth inhi-
bition studies. Furthermore, dipyridamole prevented the hypoxan-
thine-induced repletion of dGTP pools in the sensitive but not the
insensitive cells treated with lometrexol. These data suggest that,
for some tumour types, it may be possible to enhance selectively
the anti-tumour activity of lometrexol with dipyridamole.
MATERIALS AND METHODS
Cell lines
A549 (human lung carcinoma), CCRF CEM (human
lymphoblastic leukaemia), CHO Ki (Chinese hamster ovary),
HeLa (human cervical adenocarcinoma), HCT116 and HT29,
(human colonic carcinoma), KK47 (human transitional cell
bladder carcinoma, a gift from Dr S Naito, Kyushu University,
Japan), L1210 (mouse lymphocytic leukaemia) and MDA 231
(human breast carcinoma) were all adapted for growth in RPMI-
1640 medium (Life Technologies, Paisley, UK) supplemented with
10% dialysed fetal calf serum (Globepharm, Esher, UK). Routine
maintenance and all experiments were carried out in medium
containing dialysed serum to which a defined concentration of
hypoxanthine could be added. All incubations were at 37°C in a
humidified atmosphere of5% carbon dioxide in air.
Chemicals
All routine chemicals and dipyridamole were obtained from Sigma
(Poole, UK), dGTP and dextran T-70 were obtained from Pharmacia
(Milton Keynes, UK), [methyl-3H]thymidine, deoxy(1',2'-[3H]-
guanosine-5'-triphosphate), [3H]hypoxanthine and ['4C]sucrose
were obtained from Amersham, UK, and lometrexol was a kind gift
from the late G Grindey, Eli Lilly.
Growth inhibition assays
Drug incubation periods were for 48, 72 or 96 h, depending on the
growth rate ofthe cell under study, to ensure that control cultures had
undergone at least three cell doublings during the exposure period.
Exponentially growing suspension cultures
L1210 and CCRF CEM cells were seeded at a final density of
104 cells ml-', 0.5 ml per well into 24-well plates (Nunc, Life
Technologies) in medium containing hypoxanthine, dipyridamole
and lometrexol as indicated in the Results section. After 48 h
L1210 cells were counted and after 96 h CCRF CEM cells were
counted after fixation with Carnoy's fixative (methanol:acetic acid
3:1). All cell counts were made on a model ZI Coulter Counter
(Coulter Electronics, UK).
Exponentially growing cultures ofadherent cells
A549, CHO K1, HCT1 16, HeLa, HT29, KK47 and MDA 231
were seeded into 96-well plates (Nunc) at 1-1.5 x 103 cells per
well in 100g,l of medium and left to attach for 8-24 h. The
medium was replaced with medium containing the appropriate
drug concentrations. Replicate wells were fixed with Carnoy's
fixative to estimate the cell density at the start ofthe drug exposure
period. After 72 h (CHO KI) or 96 h (all others) incubation, cells
were fixed with Carnoy's fixative, washed, air dried and stained
with sulphorhodamine B, as described previously (Skehan et al,
1990). The plates were then read on a Dynatech MR7000
microtitre-plate reader using a 570-nm filter. The optical density
was measured relative to an air blank. Data were expressed as %
control by the following formula:
Per cent control = (T/C) x 100 ± ((T/C) x 100) x I((cIC)2 + (t/)2)
mean ± standard deviation
where C and c are the mean and standard deviation of the control
and T and t are the mean and standard deviation of the treated
sample respectively.
Hypoxanthine uptake measurement
Hypoxanthine uptake was measured in exponentially growing
CCRF CEM cells by a modification of the 'inhibitor-stop' method
of Domin et al (1988). Cells were centrifuged, washed and resus-
pended in ice-cold 10 mm Hepes-saline pH 7.4 buffer at a density
of 2 x 107 cells per ml. Aliquots ofcell suspension were incubated
with 1% dimethylsulphoxide (DMSO) ± 1O,M dipyridamole or
100 nm NBTI at 37°C for 5 min. An aliquot (100gl) of this was
then carefully layered onto silicone oil (sp.gr. 1.028) (BDH, UK)
overlaying 50[1 3 M potassium hydroxide in each of six 0.4-ml
microcentrifuge tubes (BDH). Uptake was initiated by adding
50 ,ul of 300 gM hypoxanthine containing 25 ,uCi ml' [3H]hypo-
xanthine and 2 ,tCi ml' ['4C]sucrose (to correct for extracellular
water) to each tube at l-s intervals (final hypoxanthine concentra-
tion = 100 gM, 106 cells per tube). Uptake was terminated by
adding 50 ,ul ice-cold 19 mM papaverine-saline (Kraupp and Marz,
1995) at 1-s intervals in reverse order. The tubes were immediately
centrifuged at 14 000 r.p.m. for 1 min and the cells allowed to lyse
in the potassium hydroxide for 1 h. The tubes were cut in the oil
layer and the bottom portion transferred to scintillation vials,
neutralized with 1 ml of0.25 M acetic acid, 10 ml ofscintillant was
added and the samples were counted on a Wallac 1410 13-counter.
Hypoxanthine uptake into A549 cells was measured using
monolayers 80-90% confluent in 24-well plates (Nunc) by a modi-
fication of published methodology (Slaughter and Barnes, 1979).
The medium was aspirated from three wells and the wells gently
washed three times with Hepes-saline buffer. Cells were then
incubated for 5 min in 0.5 ml of the same buffer with 1% DMSO
± 10 gM dipyridamole or 100gM NBTI at 37°C. Transport was
initiated by aspirating the buffer and adding 300 1l buffer
containing 100 gM hypoxanthine + 3.3 ,uCi [3H]hypoxanthine and
1 ,uCi [14C]sucrose ml' [+ 1000-fold excess (1.6 mM) sucrose to
minimize non-specific binding] with or without the desired concen-
tration of inhibitor. Uptake was terminated after 8, 12 or 16 s with
0.5 ml of ice-cold 19 mm papaverine followed by immediate aspi-
ration and two further papaverine washes. Cells were then lysed
with 1 ml of0.2 M sodium hydroxide at 60°C for 30 min. Duplicate
100 ,tl aliquots were taken for protein estimation by Coomassie
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Table 1 Lometrexol growth inhibition in combination with dipyridamole and
hypoxanthine
IC.. nM lometrexol
Cell line Lometrexol alone + Dpb +HPXc, + DP
Hela 4.4, 4.3 6.2, 5.4 8.2, 6.8
CHO Kl 28.1, 17.5 44.4, 31.8 51.7, 31.9
A549 17.4,17.4 14.2,16.1 17.6,19.4
HT29 5.4, 11.2 11.6, 8 > 1000 > 1000
HCT116 14,10 11.9,12.2 > 1000 >1000
MDA231 257, 212 243, 208 > 10 000 > 10 000
KK47 16.8, 41.9 20.9, 50.1 > 1000 > 1000
L1210 22.8, 21.8 20.6, 21.3 > 1000 > 1000
CCRF CEM 14.5,15.8 13.3, 13.8 > 1000 > 1000
aConcentration causing 50% inhibition of growth relative to control. bl0 AM
dipyridamole; c3Q ,UM hypoxanthine. Values are derived from computer-
generated curves for each cell line as shown in Figure 1 from two
independent experiments.
Blue (Pierce, UK) and 600gl was neutralized with 400 ,l of2.5%
acetic acid and the radioactivity counted as above.
Measurement of intracellular dGTP pools
Preparation ofcell extracts
A549 cells were prepared for nucleotide pool measurements as
described previously (Curtin etal, 1991). Briefly, 106 cells per well
in six-well plates (Nunc) that had been incubated for 24 or 48 h
with lometrexol, hypoxanthine and/or dipyridamole were used.
The plates were placed on ice, the medium aspirated and 0.5 ml of
0.4 M ice-cold perchloric acid added. Cells were removed from the
wells by scraping and the suspension transferred to chilled tubes
and left on ice for 30 min. After centrifugation at 1500g for 20
min, the supernatant was carefully transferred to a fresh tube and
neutralized with 0.5 vol ofice-cold 0.72 M potassium hydroxide in
0.16 M potassium bicarbonate. Samples were then stored at - 80°C
until assayed as described below.
CCRF CEM cells were incubated for 24 h with lometrexol,
hypoxanthine and/or dipyridamole, counted and 106 cells were
pelleted by centrifugation at 700g for 5 min at 4°C, the pellet was
resuspended in 0.75 ml of ice-cold 0.4 M perchloric acid and left
on ice for 30 min. The suspensions were centrifuged and neutral-
ized and stored as above.
Sodium periodate treatment
The neutralized extracts were centrifuged for 10 min at
10000 r.p.m. at 4°C and ribonucleotides removed by sodium
periodate as described by Garret and Santi (1979). Briefly, 20 ml
of 0.5 M sodium periodate was added to the supernatant, vortex
mixed and left at room temperature for 5 min. An aliquot (25 ml)
of 4 M methylamine, pH 7.5, was added, the tubes vortex mixed
and incubated at 37°C for 15-20 min. The extracts were frozen at
- 70°C overnight before radioimmunoassay.
dGTP radioimmunoassay
The dGTP antiserum was raised in a New Zealand White rabbit
(8764) in response to a prime and one boost with a conjugate of
dGTP-ovalbumin (12 moles per mole) prepared with a water
soluble carbodiimide condensation reaction (Holloran and Parker,
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Figure 1 Growth inhibition of (A) A549 and (B) CCRF CEM cells exposed
to lometrexol ± 10 gm dipyridamole and/or 30 ,um hypoxanthine as measured
by sulphorhodamine B staining. Lometrexol alone, -; lometrexol + 10 ,um
dipyridamole, *; lometrexol + 30gm hypoxanthine, 0; lometrexol + 10gm
dipyridamole and 30gim hypoxanthine, 0. The combination of lometrexol
with dipyridamole and hypoxanthine is shown with a thick solid line to
highlight the different response to this combination in the different cell lines.
The data shown are from a single representative experiment, points are
means ± s.d. from ten replicate wells
(Piall et al, 1986, 1989) except that booster injections were given
at 2-3-month intervals.
The radioimmunoassay was set up as described for dCTP (Piall
et al, 1986) and dUTP (Piall et al, 1989). Briefly, standard dGTP
was diluted with assay diluent, 0.3 M potassium hydrogen phos-
phate, to cover the range 0.1-10 pmol ml-l and cell extracts were
diluted 1:5, 1:10 and 1:25 in the same solution. The antiserum was
diluted in water (1:120)just before use so that approximately 30%
of total radioactivity was bound (Bo) to antibody. The radio-
labelled dGTP was diluted with water so that approximately
0.1 pmol (0.1 ml) was added to each assay tube. An aliquot
(0.1 ml) of diluted standards and samples was added in duplicate
to numbered LP3 tubes (Luckham) with 0.3 ml of assay diluent,
0.1 ml of diluted antiserum and 0.1 ml of diluted label; the tubes
were vortexed and left on ice for 2 h. Each assay included total
counts and non-specific binding tubes containing only the radio-
label and buffer, and zero binding tubes (BO) that contained radio-
label and antiserum but no dGTP. The antibody bound ligand was
separated fromunbound ligandby the addition ofice-colddextran-
coated charcoal [2.5% (w/v) activated charcoal coated with 0.25%
(w/v) Dextran T-70] to all but the total counts for 10 min. After
centrifugation at 2500 r.p.m. for 10 min at 4°C, 500p1 aliquots of
supematant were taken from each assay tube for scintillation
counting using 2.5 ml of Hionic-Fluor scintillant (Canberra-
Packard). The dNTP concentrations in the cell extracts were calcu-
lated from the standard curve using a data reduction programme,
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which utilized a four parameter logistic plot (RiaSmart, Canberra-
Packard), and the amount ofdGTP per 106 cells calculated.
The dGTP antiserum cross-reacted with dGDP by 33.3% but
cross-reaction with dGMP, GTP, dCTP, dATP, dUTP, TTP,
deoxyguanosine, deoxyadenosine, guanosine and adenosine was
less than 1% (Aheme et al, 1995). Thus, as no chromatographic
separation of dGTP from dGDP was undertaken, some inter-
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Figure 2 Hypoxanthine uptake into (A) CCRF CEM and (B) A549 cells in
the absence of inhibitor E; in the presence of 100 nm, NBTI A; or 10gM
dipyridamole 0. Error bars are (B) ± s.d. from triplicate samples, (A) not
shown for clarity of presentation
although this is likely to be minimal as the dGDP pool is smaller
than the dGTP pool (Tyrsted, 1975). The recovery of dGTP (10
and 20 pmol) added to cell pellets and treated as described was
78.2%. An aqueous dGTP solution (nominal value 2.5 pmol ml-')
was included in each assay as a control sample and gave an intra-
and inter-assay variation of7.3% (n = 7) and 6.5% (n = 10) respec-
tively. The standard curve ranged from 0.05 to 10 pmol ml' with a
sensitivity of0.1 pmol ml' calculated from a 3-s.d. fall in binding
from the mean Bo value. This is equivalent to a limit of detection
of0.4 pmol per 106 cells at an extract dilution of 1:5. dGTP pools
in untreated cells measured by radioimmunoassay were similar to
those reported for several mouse and human tumour cell lines
measured by either high performance liquid chromatography
(HPLC) (Bokkerink et al, 1986; Mattano et al, 1990) or DNA
polymerase assays (Ross et al, 1981; Cohen et al, 1993).
RESULTS
Growth inhibition studies
Growth inhibition curves are shown for A549 and CCRF CEM
only (Figure 1), with a summary oftheIC50 values obtained for all
cells given in Table 1. In all cells, 30 ,UM hypoxanthine completely
reversed growth inhibition by lometrexol and near 100% control
growth was obtained for cells treated with up to 10 ,UM lometrexol
in the presence of 30 ,UM hypoxanthine. In all cells, the curves
obtained for lometrexol + 10,M dipyridamole were almost
identical to those obtained for lometrexol alone, indicating that
dipyridamole does not affect lometrexol cytotoxicity per se.
Differences between the cell lines were observed when the
combination of lometrexol + 30,M hypoxanthine and 10,M
dipyridamole was used. In A549 (Figure IA), CHO and HeLacells
dipyridamole completely blocked the rescue by hypoxanthine and
the curves were the same as for lometrexol ± dipyridamole. In
contrast, dipyridamole had no effect in CCRF CEM cells (Figure
1B) or on HT29, HCT1 16, MDA 231, KK47 and L1210 cells,
and the curves were identical to those obtained with lometrexol
+ 30gM hypoxanthine, i.e. the cells were still completely rescued
from lometrexol growth inhibition. The response to dipyridamole
was either all or nothing and no intermediate responses were seen
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Figure 3 Intracellular dGTP in CCRF CEM cells (0) and A549 cells (U)
exposed for 24 and 48 h respectively, to lometrexol (1 gM) alone or in the
presence of hypoxanthine (30gM) and/or dipyridamole (10gM). Results are
expressed as a percentage of the appropriate control: i.e. lometrexol alone
(LOM) is expressed as % drug-free control, lometrexol + dipyridamole (+DP)
as % dipyridamole alone control and lometrexol + hypoxanthine (+HPX) and
lometrexol + hypoxanthine + dipyridamole (+HPX + DP) as % hypoxanthine
alone control. Data points are from triplicate periodated cell extracts, assayed
at three dilutions in duplicate from a single representative experiment out of
two that were performed with similar results. Error bars are standard
deviations calculated to take account of control variation as described in
Materials and Methods
Hypoxanthine transport studies
The marked contrast between the response of A549, HeLa and
CHO cells and that ofL1210, CCRF CEM, HT29, HCT1 16, MDA
231 and KK47 cells to the combination of lometrexol, hypo-
xanthine and dipyridamole suggested cell-specific differences
in the sensitivity of hypoxanthine transport to dipyridamole.
Hypoxanthine uptake is most easily measured in suspension
cultures. For this reason, CCRF CEM cells were chosen as the
representative cell line from the dipyridamole-insensitive group.
A549, CHO and HeLa cells do not grow in suspension, which
makes rapid transport measurements more difficult. A549 cells
were selected to represent this group ofcells as they have a similar
growth rate to CCRF CEM cells and similar sensitivity to lome-
trexol (Table 1). Hypoxanthine uptake into A549 and CCRF CEM,
as representative of the two types of cell, was measured using
rapid, inhibitor-stop techniques. Transport studies used phosphate-
free buffer to minimize phosphoribosylation and papaverine was
used to terminate uptake.
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Figure 4 Proposed mechanism of nucleoside and hypoxanthine transport in the two different (dsand di) cell types: the cell type represented on the left has a
high proportion of ei, in addition to es, nucleoside transporters and nucleosides, i.e. thymidine (TdR) enter via both. Hypoxanthine (HPX) enters via the ei
nucleoside transporter in these cells. As both es and einucleoside transport is sensitive to inhibition by dipyridamole hypoxanthine uptake is also inhibited and
the transporter phenotype of these cells is ds. In contrast, in the cell type represented on the right there are abundant estransporters forample nucleoside
uptake but insufficient ei nucleoside transporters to allow adequate hypoxanthine uptake and so a different carrier is used. This carrier is not inhibited by
dipyridamole and in this case the hypoxanthine transport phenotype is di
Hypoxanthine uptake into CCRF CEM cells grown in suspen-
sion could be measured at 2-s intervals for 12 s aftercentrifugation
through silicone oil. The initial uptake was very rapid and, as the
intracellular volume of 106 CCRF CEM cells is 1-1.5 ,ul, equili-
bration with the extracellular concentration is reached within 4-
6 s. Further accumulation must therefore be due to other factors,
e.g. hypoxanthine guanine phosphoribosyl transferase activity,
despite the use ofphosphate-free buffer. Hypoxanthine uptake was
only slightly (5-10%) inhibited by 10 tM dipyridamole and there
was no inhibition by 100 nM NBTI, a potent nucleoside transport
inhibitor (Figure 2A).
A549 cells could notbe assayed using thecentrifugation method
as they are adherent cells, trypsinization might have altered the
transport protein and cell scraping resulted in too high afraction of
dead cells. Instead, hypoxanthine uptake was measured in A549
cells growing in multiwell plates at 8, 12 and 16 s. The protein
content of A549 cells is approximately 500 jg 10-6 cells, thus
0.2 pmol mg-' protein is equivalent to 100 pmol 0I cells. We have
not measured the intracellular water in these cells, but Coulter esti-
mations suggest that they are somewhat larger than CCRF CEM
cells. Thus, equilibration with the extracellular hypoxanthine does
not appear to occur until at least the 16-s time interval, possibly
even later. As the cells were a monolayer on aplastic substratum, a
smaller fraction ofthe plasma membrane was available to conduct
transport. This could explain the slower uptake of extracellular
hypoxanthine. Alternatively, the transport of hypoxanthine might
be mediated by different carriers, with different kinetic properties,
in the two cell types. In A549 cells, hypoxanthine uptake was
completely inhibited by 10gM dipyridamole, but 100 nM NBTI
inhibited hypoxanthine uptake by only about 20% (Figure 2B).
Intracellular dGTP pool measurement
In view ofthe differences in the inhibition ofhypoxanthine uptake
by dipyridamole between A549 and CCRF CEM cells and the
different sensitivities of these cells to the combination of lome-
trexol, dipyridamole and hypoxanthine, we also investigated the
effect on dGTP pools in these cells. Intracellular dGTP pools were
measured afterincubation ofA549 andCCRFCEM cells with 1 gM
lometrexol ± 30gM hypoxanthine ± 10 jiM dipyridamole (Figure
3). In A549 cells, dGTP pools exhibited only modest changes at
24 h, but they were qualitatively similar to those at 48 h (data not
shown). Controls were drug-free: 30gM hypoxanthine alone and
10 iM dipyridamole alone. Drug-free control dGTP pools were
12.9 ± 0.3 pmol per 106 CCRF CEM cells, and for A549 were
6.3 ± 1.0 and 3.6 ± 0.3 pmol per 106 cells at 24 and 48 h respec-
tively. The reduction in control intracellular dGTP in A549 cells
from 24 to 48 h may reflect the fact that the cells were confluent by
48 h and may therefore have reduced intracellular dNTP content.
Exposure to lometrexol for 24 h caused the dGTP pool in CCRF
CEM cells tobereduced to 30% ofcontrollevels. InA549cells,48 h
exposure to lometrexol also reduced the dGTP pool to a third of
control levels. Co-incubation with dipyridamole did not cause a
significant further reduction. Co-incubation with hypoxanthine
repleted the dGTP pool in both cell lines to levels that were not
significantly different from untreated control levels. Co-incubation
withhypoxanthine anddipyridamole allowednearly totalrepletionof
dGTP in CCFR CEM cells and the dGTP pools in cells treated with
lometrexol and hypoxanthine were not significantly different with or
without dipyridamole. In contrast, repletion of the dGTP pool was
completely blocked by dipyridamole in A549 cells, and the dGTP
pools in these cells treated withlometrexol, hypoxanthine anddipyri-
damole were significantly differentfromthose exposedto lometrexol
and hypoxanthine but not from those exposed to lometrexol and
dipyridamole. Thus, dipyridamole can prevent hypoxanthine reple-
tion ofdGTPpools in A549 cells but not CCRF CEM cells.
DISCUSSION
In all of the cells studied, exogenous hypoxanthine could reverse
lometrexol growth inhibition, demonstrating that the inhibition of
de novo purine biosynthesis could be overcome by purine salvage
in all these cell types and there were no salvage pathway defective
mutants within the group studied. In the absence of salvageable
purines, co-incubation with dipyridamole and lometrexol resulted
in a similar dose response to lometrexol alone in all the cell types,
indicating that there was neither any antagonism nor any synergy
ofdipyridamole with lometrexol in any ofthe cells.
British Journal ofCancer (1997) 76(10), 1300-1307 0Cancer Research Campaign 1997Selective potentiation oflometrexol bydipyridamole 1305
However, on the basis of their response to the combination of
lometrexol, hypoxanthine and dipyridamole the cells under
investigation fell into two categories. In the first (A549, HeLa and
CHO), growth inhibition was the same as seen with lometrexol
alone despite the presence of adequate amounts of salvageable
purines, i.e. dipyridamole completely blocked hypoxanthine
rescue. In the second (CCRF CEM, L1210, HCT1 16, HT29, MDA
231 and KK47), despite the presence of dipyridamole, hypo-
xanthine rescued the cells from lometrexol and growth was not
impeded, i.e. dipyridamole had absolutely no effect. An inter-
mediate response (partial reversal ofhypoxanthine rescue) was not
seen in any of the cell lines.
The hypothesis that this effect was due to differential sensitivity
of the hypoxanthine uptake system to dipyridamole was tested
using A549 and CCRF CEM cells as representatives of the two
categories. In addition, we also measured the effect of lometrexol
on dGTP in the presence and absence of hypoxanthine and/or
dipyridamole in these two cell lines.
Hypoxanthine uptake into A549 cells was completely blocked
by dipyridamole, and in these cells dipyridamole prevented the
hypoxanthine repletion of dGTP pools reduced by lometrexol. We
assume that this was also the case for HeLa and CHO cells,
in which dipyridamole also prevented hypoxanthine rescue
from lometrexol, although we have not tested this directly.
Hypoxanthine transport in these cells is ds.
Conversely, in CCRF CEM cells dipyridamole had only a
modest effect on hypoxanthine uptake, i.e. the majority of hypo-
xanthine transport was di, and in these cells dipyridamole failed to
prevent the hypoxanthine repletion of dGTP pools reduced by
lometrexol. Similarly, hypoxanthine uptake in L1210, HeLa,
HCTI 16, HT29, MDA 231 and KK47 must be largely di,
although, again, this has not been directly tested.
Other studies on the uptake of hypoxanthine in a variety of cells
have found similar differences in sensitivities to dipyridamole.
Plagemann et al (1988) reviewed the data and found that cells
belonged to two groups: group I (equivalent to ds), in which
hypoxanthine uptake was blocked by dipyridamole, included
NISI-67 and HCT (rat hepatoma cells) CHO, CHL (Chinese
hamster lung) and Ehrlich ascites cells; and group II (equivalent to
di), in which hypoxanthine uptake was not inhibited by dipyrid-
amole, included L929 (murine connective tissue), P388 (murine
leukaemic cells) and human red blood cells. In addition, a dipyrid-
amole-sensitive concentrative hypoxanthine transporter has
been described in cultured renal epithelial cells (Griffith and
Jarvis, 1993)
This inhibitor sensitive/insensitive hypoxanthine transport is
analogous to the equilibrative nucleoside transport systems of
mammalian cells, in which transport is sensitive (es) or insensitive
(ei) to inhibition by NBTI. Different cell lines have different
proportions of es and ei. Phenotypes may be explored as NBTI
selectively inhibits the es transporter, p-chloromercuriphenyl-
sulphonate (pCMPS) selectively inhibits the ei transporter and
dipyridamole inhibits both (Belt, 1983; Belt et al 1993 and refer-
ences therein).
Plagemann et al (1988) note that group I cells (in which hypox-
anthine transport is ds) have a high proportion ofNBTI-insensitive
(ei) nucleoside transport. As hypoxanthine transport was insensi-
tive to NBTI but inhibited by uridine in these cells, they suggest
that hypoxanthine enters via the ei nucleoside transporter in such
cells. In cells with a low proportion of ei nucleoside transporters,
there is presumably insufficient capacity to transport hypoxanthine
adequately via this route and another transporter system (di) is
employed (Figure 4). We found that dipyridamole prevented
hypoxanthine rescue of CHO and HeLa cells, indicating that
hypoxanthine transport is ds. Plagemann and Wohlhueter (1984b)
calculate that in CHO cells 30-40%, and in HeLa cells 40-50%, of
nucleoside transport is ei. Our own studies of thymidine transport
in the di cell line, CCRF CEM (data not shown) demonstrated that
thymidine uptake is inhibited > 90% by 10 nM NBTI, inhibited
10% by pCMPS and inhibited 100% by dipyridamole. This indi-
cates that < 10% of the transporters are ei, and this is presumably
insufficient to allow adequate hypoxanthine uptake via this route.
In CCRF CEM cells, hypoxanthine uptake was inhibited < 10% by
10 gM dipyridamole, indicating that some hypoxanthine enters via
the ei nucleoside transporter but that > 90% enters via another
route. These data are consistent with the hypothesis that ds hypox-
anthine transport is via the ei nucleoside transporter and di trans-
port is via another carrier unrelated to the nucleoside transporter.
We observed that lometrexol depleted dGTP pools and that co-
incubation with hypoxanthine repleted them in both cell lines. This
repletion could be blocked in A549 cells but not in CCRF CEM
cells, corresponding to the observed differential effects of dipyri-
damole on hypoxanthine transport and rescue from lometrexol in
these two cell lines. Reduced intracellular GTP in CCRF CEM
cells treated with lometrexol has been demonstrated previously
(Pizzorno et al, 1991), however these authors reported that there
was a concurrent increase in both dGTP and dATP. In another
study, dGTP pools were unaffected by lometrexol (Sokoloski et al,
1993), and others have reported that lometrexol causes a decrease
in dATP (Kwok and Tattersall, 1991). To the best of our knowl-
edge, the data presented here are the first demonstration of a deple-
tion of dGTP pools by lometrexol. We observed that in control
A549 cells the dGTP pools were lower at 48 h than at 24 h. The
cells were becoming confluent at this time, and this may have been
responsible as cells in a stationary culture have greatly reduced
dNTP pools compared with exponentially growing cells (Spyrou
and Reichard, 1988; Benz and Cadman, 1991; GW Aherne,
unpublished data).
The significance of reduced intracellular dGTP in relation to the
cytotoxicity oflometrexol is outside the scope ofthe present study;
nevertheless, both the restoration ofthe dGTP pool and the preven-
tion of cytotoxicity was achieved by co-incubation of
lometrexol-treated cells with hypoxanthine.
It is apparent that the sensitivity to the combination of lome-
trexol, hypoxanthine and dipyridamole is by virtue of the hypo-
xanthine transporter phenotype, either ds or di. The finding by
Chan and Howell (1990) that dipyridamole inhibited hypoxanthine
uptake in 2008 human ovarian carcinoma cells is similar to our
observed blocking of hypoxanthine rescue by dipyridamole in
Chinese hamster ovary cells. Similarly, we found that human lung
carcinoma, A549, cells had ds hypoxanthine transport and
Slaughter and Barnes (1979) found hypoxanthine transport was
inhibited by dipyridamole in Chinese hamster lung fibroblasts.
Thus, hypoxanthine uptake is sensitive to dipyridamole in some
cell types ofboth human and rodent origin.
In contrast, our observation that L1210 (murine) and CCRF
CEM (human) leukaemic cells are di is similar to results obtained
with P388 murine leukaemic cells, which have been shown to have
dipyridamole-insensitive hypoxanthine transport (Plagemann et al,
1988), i.e. leukaemic cells are di in both humans and rodents.
Similarly, HT29 and HCT116 - both human colon carcinoma -
are insensitive to dipyridamole, confirming the findings of
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Van Mouweric et al (1987) that dipyridamole did not inhibit
hypoxanthine uptake in HCT116 cells.
It is important to note that the dose-limiting clinical toxicities of
lometrexol are myelosuppression and gastrointestinal toxicity
(Nelson et al, 1990; Young et al, 1990; Paganini et al, 1992; Ray et
al, 1993). If normal bone marrow progenitor cells and intestinal
crypt cells have dipyridamole-insensitive hypoxanthine transport,
like the tumours derived from them, then the combination oflome-
trexol, hypoxanthine and dipyridamole might not be toxic in these
tissues. For bone marrow at least, all studies to date indicate that
progenitor cells possess little or no ei (and hence ds) transporters.
These studies were performed using the granulocyte-macrophage
progenitor cell colony-forming assay (CFU-GM) as bone marrow
is a heterogeneous population of cells and it is not feasible to
isolate sufficient quantities of progenitor cells to measure nucleo-
side transport directly. However, in CFU-GM assays, NBTI
(which only inhibits es nucleoside transport) protected both mouse
and human bone marrow stem cells from tubercidin (an adenosine
analogue that enters via the nucleoside transporter) cytotoxicity to
the same extent as in CCRF CEM cells (Janowska-Wieczorek and
Cass, 1987; Marina and Belt, 1991). NBTI also potentiated
methotrexate cytotoxicity by inhibition of thymidine salvage in
mouse bone marrow stem cells (Marina and Belt, 1991).
Moreover, the hypoxanthine concentration in the bone marrow
is 10-30gM, at least ten times higher than in plasma, due to
erythrocyte nuclear degradation and white cell death (Tattersall et
al, 1983). Thus, normal bone marrow hypoxanthine concentration
might be sufficient to ameliorate lometrexol plus dipyridamole
toxicity at concentrations that would prove toxic to cancer cells of
the ds phenotype. Collectively, these observations suggest that
further work on normal bone marrow progenitor cells and
intestinal crypt cells is justified to determine if it is possible to
achieve the selective enhancement of lometrexol toxicity by
dipyridamole to certain tumours while not preventing rescue of
bone marrow by hypoxanthine.
ABBREVIATIONS
NBT1, nitrobenzylthioinosine; ds, dipyridamole-sensitive hypo-
xanthine transport; di, dipyridamole insensitive hypoxanthine
transport; es, equilibrative-sensitive nucleoside transport; ei,
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